|
India News Releases
|
(India.CityRegions.Com, December 15, 2016 ) Non-Hodgkin lymphoma (also known as non-Hodgkin's lymphoma, NHL, or sometimes just lymphoma) is a cancer that starts in cells called lymphocytes, which are part of the body's immune system. Symptoms depend on what area of the body is affected by the cancer and how fast the cancer is growing. Symptoms may include night sweats (soaking the bed sheets and pajamas even though the room temperature is not too hot),fever and chills that come and go, itching, swollen lymph nodes in the neck, underarms, groin, or other areas, weight loss, coughing or shortness of breath if the cancer affects the thymus gland or lymph nodes in the chest, putting pressure on the windpipe (trachea) or other airway, abdominal pain or swelling, leading to loss of appetite, constipation, nausea, and vomiting and headache, concentration problems, personality changes, or seizures if the cancer affects the brain. Treatment includes surgery, radiation therapy and chemotherapy.
Report Highlights
Publisher's Pharmaceutical and Healthcare latest pipeline guide Non-Hodgkin Lymphoma - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Non-Hodgkin Lymphoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Non-Hodgkin Lymphoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Non-Hodgkin Lymphoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 10, 2, 23, 129, 99, 5, 107, 15 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 12, 15, 9 and 5 molecules, respectively.Non-Hodgkin Lymphoma.
Non-Hodgkin Lymphoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
For more information about this report at http://www.reportsweb.com/non-hodgkin-lymphoma-pipeline-review-h2-2016
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Non-Hodgkin Lymphoma (Oncology). - The pipeline guide reviews pipeline therapeutics for Non-Hodgkin Lymphoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Non-Hodgkin Lymphoma (Oncology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Non-Hodgkin Lymphoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Non-Hodgkin Lymphoma (Oncology)
Request a sample copy at http://www.reportsweb.com/inquiry&RW0001499749/sample
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Non-Hodgkin Lymphoma (Oncology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Non-Hodgkin Lymphoma (Oncology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Companies profiles
AB Science SA AbbVie Inc Acetylon Pharmaceuticals Inc Actelion Ltd Actinium Pharmaceuticals Inc ADC Therapeutics Sarl Affimed GmbH Allinky Biopharma Altor BioScience Corp Amgen Inc Angimmune LLC arGEN-X BV Arno Therapeutics Inc Arrien Pharmaceuticals LLC Arvinas Inc Asana BioSciences LLC Astellas Pharma Inc Astex Pharmaceuticals Inc AstraZeneca Plc Atara Biotherapeutics Inc Aurigene Discovery Technologies Ltd Bayer AG BeiGene Ltd Bellicum Pharmaceuticals Inc Bio-Path Holdings Inc BioAtla LLC Biocon Ltd Biogen Inc Biogenomics Ltd BioInvent International AB BioLineRx Ltd Bionovis SA BioNTech AG BioSight Ltd Biothera Pharmaceutical Inc bluebird bio Inc Boehringer Ingelheim GmbH Boston Biomedical Inc
Ask for Discount at http://www.reportsweb.com/inquiry&RW0001499749/discount
List of Figures
Number of Products under Development for Non-Hodgkin Lymphoma, H2 2016 58 Number of Products under Development for Non-Hodgkin Lymphoma - Comparative Analysis, H2 2016 59 Number of Products under Development by Companies, H2 2016 60 Number of Products under Investigation by Universities/Institutes, H2 2016 77 Comparative Analysis by Late Stage Development, H2 2016 79 Comparative Analysis by Clinical Stage Development, H2 2016 80 Comparative Analysis by Early Stage Products, H2 2016 81 Assessment by Monotherapy Products, H2 2016 332 Assessment by Combination Products, H2 2016 333 Number of Products by Top 10 Targets, H2 2016 334 Number of Products by Stage and Top 10 Targets, H2 2016 334 Number of Products by Top 10 Mechanism of Actions, H2 2016 365 Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 365 Number of Products by Top 10 Routes of Administration, H2 2016 395 Number of Products by Stage and Top 10 Routes of Administration, H2 2016 395 Number of Products by Top 10 Molecule Types, H2 2016 397 Number of Products by Stage and Top 10 Molecule Types, H2 2016 397
Purchase Complete Report at http://www.reportsweb.com/buy&RW0001499749/buy/2000
ReportsWeb.com
Priya Sisodia
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com
|
|
|
India RSS Feed Marketpalce
|
India News Headlines
Daily news from India: arts, business, culture, politics, science, technology & more.
Free Sales & Marketing Magazines
Get free publications about marketing, sales and customer relations management.
Submit RSS feed on India. Have your feed on news, products or services displayed under this marketpalce and have your feed on a full page updated daily.
|
|
India Business News by Major Cities
|
|
|
Listen to GroupWeb Radio
INDIA BUSINESS TV
|